Witzig T E, Phyliky R L, Li C Y, Homburger H A, Dewald G W, Handwerger B S
Am J Hematol. 1986 Feb;21(2):139-55. doi: 10.1002/ajh.2830210204.
T-cell chronic lymphocytic leukemia (T-CLL) accounts for about 2% of the various types of CLL and can be subtyped into helper/inducer (h/i) and cytotoxic/suppressor (c/s) cell membrane phenotypes. Seven patients with CLL were shown to have T-CLL with a h/i cell membrane phenotype; four with monoclonal antibody reagents and three by demonstration of the E-rosette receptor and focal acid alpha naphthyl acetate esterase activity. The clinical courses, treatment responses, and laboratory findings of these seven patients were reviewed to determine the prognosis and unique clinicopathologic features of this subtype. Two patients presented with skin rashes, and five were diagnosed during evaluation for other medical problems. Initially, four patients had splenomegaly and two had lymphadenopathy, but none of the patients had hepatomegaly. Morphologic examination revealed uniform, small lymphocytes in three patients, and the lymphocytes had nuclear indentations in four patients. Sera from the three patients tested were negative for antibody to the human T-cell leukemia/lymphoma virus I. Peripheral blood mononuclear cells from one patient showed normal interleukin-2 production and lacked antibody-dependent cell-mediated cellular cytotoxicity and natural killer activity. Cytogenetic analysis was done on one patient, revealing an abnormal clone with several chromosomal abnormalities, including an X;14 translocation with a break point at 14q11. All patients required chemotherapy, and all died a median of 21 months from the time of diagnosis. The findings in these patients, in addition to those in 31 patients described in the literature, indicate that h/i T-CLL is associated with a poor prognosis and has distinct clinical and pathologic features that separate it from c/s T-CLL, adult T-cell leukemia/lymphoma, the cutaneous T-cell lymphomas, and B-CLL.
T细胞慢性淋巴细胞白血病(T-CLL)约占各类慢性淋巴细胞白血病的2%,可分为辅助/诱导型(h/i)和细胞毒性/抑制型(c/s)细胞膜表型。7例慢性淋巴细胞白血病患者被证实患有h/i细胞膜表型的T-CLL;4例通过单克隆抗体试剂确诊,3例通过E玫瑰花结受体及酸性α萘乙酸酯酶活性的检测确诊。回顾这7例患者的临床病程、治疗反应及实验室检查结果,以确定该亚型的预后及独特的临床病理特征。2例患者出现皮疹,5例在评估其他疾病时被诊断出。最初,4例患者有脾肿大,2例有淋巴结病,但均无肝肿大。形态学检查显示,3例患者的淋巴细胞均一、较小,4例患者的淋巴细胞有核凹陷。检测的3例患者血清中人类T细胞白血病/淋巴瘤病毒I抗体均为阴性。1例患者外周血单个核细胞白细胞介素-2产生正常,缺乏抗体依赖性细胞介导的细胞毒性及自然杀伤活性。对1例患者进行了细胞遗传学分析,发现一个异常克隆,有多个染色体异常,包括X;14易位,断点在14q11。所有患者均需化疗,自诊断起中位生存期为21个月,均已死亡。这些患者的研究结果,以及文献中描述过的另外31例患者的结果,均表明h/i T-CLL预后较差,具有独特的临床和病理特征,使其有别于c/s T-CLL、成人T细胞白血病/淋巴瘤、皮肤T细胞淋巴瘤及B-CLL。